文献速递临床微生物分子诊断质量管理与危急值

韩国产超广谱β-内酰胺酶大肠埃希菌的分子流行病学:Kor-GLASS报告

Molecular Epidemiology of Extended-spectrum β-Lactamase-producing Escherichia coli in South Korea: A Korean Global Antimicrobial Resistance Surveillance System Report.
PubMed 文献 · Ann Lab Med · 2025-11-05

该研究基于韩国Kor-GLASS网络2017—2021年8家哨点医院收集的9232株非重复血流感染大肠埃希菌,分析其对头孢噻肟和头孢他啶的耐药率、序列型及ESBL基因型。结果显示头孢噻肟耐药率为36.4%,ST131为头孢噻肟耐药菌中最常见序列型(64.8%),并鉴定出年龄>65岁、医院获得性感染和ICU入住为耐药风险因素。

要点

  • 韩国血流感染大肠埃希菌对头孢噻肟耐药率达36.4%,对头孢他啶为11.4%。
  • 头孢噻肟耐药菌中ST131占64.8%,其次为ST1193和ST69。
  • 年龄>65岁、医院获得性感染和ICU入住是头孢噻肟耐药独立风险因素。

核心结论

  • 韩国血流感染大肠埃希菌中产ESBL菌株以ST131为主,且不同序列型携带不同CTX-M基因型,需持续监测以指导经验治疗和感染控制。

研究设计与样本

  • 基于韩国Kor-GLASS网络8家哨点医院2017—2021年收集的非重复血流感染大肠埃希菌9232株,进行药敏试验、多位点序列分型和β-内酰胺酶基因分型。

主要发现

  • 9232株大肠埃希菌血流分离株对头孢噻肟耐药率为36.4%,对头孢他啶耐药率为11.4%。
  • 头孢噻肟耐药菌中ST131占64.8%(2180/3363),ST1193占5.3%(177株),ST69占5.1%(170株)。
  • 年龄>65岁(aOR 1.36)、医院获得性感染(aOR 2.55)和ICU入住(对比普通病房,aOR 1.34)是头孢噻肟耐药的显著风险因素。
  • ST131、ST648、ST405和ST410耐药菌常携带blaCTX-M-15,ST1193和ST68多携带blaCTX-M-27,ST457和ST5150多携带blaCTX-M-55。

临床怎么用

  • 对年龄>65岁、医院获得性感染或ICU患者经验性治疗时应考虑产ESBL大肠埃希菌风险。
  • 持续监测产ESBL大肠埃希菌的分子流行病学有助于指导经验治疗和感染控制政策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is among the most important multidrug-resistant pathogens causing bloodstream infections (BSIs). Cefotaximase (CTX-M) enzymes are the most common and highly diverse ESBL family in E. coli. CTX-M-15 in group CTX-M-1 and CTX-M-14 in group CTX-M-9 are the most extensively disseminated enzymes. Multidrug-resistant E. coli strains complicate empirical therapy and increase healthcare burden globally and in Korea. We investigated the molecular epidemiology, sequence types (STs), and ESBL genotypes of E. coli bloodstream isolates in Korea and identified clinical risk factors for cefotaxime resistance. METHODS: We collected all non-duplicated isolates of E. coli and related clinical information from patients with BSIs at eight sentinel hospitals in the Korean Global Antimicrobial Resistance Surveillance System (Kor-GLASS) collection network during 2017-2021. Duplicate isolates were removed to ensure representativeness of the data. Antimicrobial susceptibility was tested using disk diffusion tests, and multilocus sequence typing and beta-lactamase genotyping were performed. RESULTS: Among 9,232 E. coli blood isolates, resistance rates to cefotaxime and ceftazidime were 36.4% and 11.4%, respectively. Among the clinical factors, age >65 yrs (adjusted odds ratio [aOR], 1.36), hospital-origin infection (aOR, 2.55), and admission type (intensive care unit [ICU] vs. general ward; aOR, 1.34) were significant cefotaxime resistance risk factors. ST131 was the most prevalent among cefotaxime-resistant E. coli (64.8%, 2,180/3,363), followed by ST1193 (5.3%, N=177), and ST69 (5.1%, N=170). ST131, ST648, ST405, and ST410 cefotaxime-resistant E. coli isolates frequently harbored blaCTX-M-15, whereas ST1193 and ST68 showed a high proportion of blaCTX-M-27 carriers, and most ST457 and ST5150 isolates carried blaCTX-M-55. CONCLUSIONS: Continuous monitoring of ESBL-producing E. coli is required to prevent further dissemination, guide empirical therapy, inform infection control policies, and ensure early detection of multidrug-resistant clones with the potential for widespread transmission.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Kim D, Lee S, Hong JS, et al. Molecular Epidemiology of Extended-spectrum β-Lactamase-producing Escherichia coli in South Korea: A Korean Global Antimicrobial Resistance Surveillance System Report. Ann Lab Med. 2025. PMID: 41189390. doi:10.3343/alm.2025.0145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。